Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10594701 | Bioorganic & Medicinal Chemistry Letters | 2012 | 4 Pages |
Abstract
KIAA1363 is a serine hydrolase whose activity has been shown to be positively associated with tumor cell invasiveness. Thus, inhibitors of KIAA1363 represent a novel targeted therapy approach towards cancer. AX11890 ((1-bromo-2-naphthyl) N,N-dimethylcarbamate) was identified as a KIAA1363 inhibitor with an IC50 value of 1.2 μM and was shown using ESI-MS to carbamylate the catalytic residue Ser191. SAR studies explored both substitution of the 1-bromo group and derivatization of the 6-position. Activity-based protein profiling demonstrated AX13057 inhibited tumor-localized KIAA1363 in SK-OV-3 xenograft-bearing mice.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Kevin R. Shreder, Emme C.K. Lin, Jiangyue Wu, Julia Cajica, Christopher M. Amantea, Yi Hu, Eric Okerberg, Heidi E. Brown, Lan M. Pham, De Michael Chung, Allister S. Fraser, Ethel McGee, Jonathan S. Rosenblum, John W. Kozarich,